Centre Hospitalier Universitaire Vaudois

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Estimates of the Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease

  NCT06431971· Phase 2· InnoMedica Schweiz AG· Source

• Not yet recruiting

  EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases

  NCT05688241· Phase 1/2· University Hospital, Basel, Switzerland· Source

• Recruiting

  MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.

  NCT07574047· Phase 2· Swiss Cancer Institute· Source

• Not yet recruiting

  VALSE: Integration of Neuromodulation and Exoskeleton Systems for Mobility in Individuals With Chronic Spinal Cord Injury

  NCT07745686· Ecole Polytechnique Fédérale de Lausanne· Source

• Recruiting

  Brain-controlled Spinal Cord Stimulation in Participants With Chronic Stroke for Lower and Upper Limb Rehabilitation

  NCT07610850· Ecole Polytechnique Fédérale de Lausanne· Source

• Not yet recruiting

  Redo-Pulmonary Vein Isolation With Versus Without Posterior Wall Ablation - The REDO-PIFPAF-PFA Study

  NCT07745543· University Hospital, Basel, Switzerland· Source

• Enrolling by invitation

  Feasibility of Non-invasive Hemodynamic Assessment by 5D Flow in Congenital Heart Disease

  NCT07742046· Tobias Rutz· Source

• Recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

  NCT07365241· Phase 3· AbbVie· Source

• Recruiting

  Personalized Rehabilitation With Organ-Preserving Robotic RESA in Head and Neck Cancer

  NCT07546045· Christian Simon· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  HORUS-Cytomegalovirus Open Proof-of-concept Exploratory Trial

  NCT07570433· Phase 4· Oriol Manuel· Source

• Recruiting

  ARC-IM Therapy To Support and Promote Recovery of Ambulatory Functions in People With Subacute and Chronic Spinal Cord Injury

  NCT07234903· Ecole Polytechnique Fédérale de Lausanne· Source

• Not yet recruiting

  Effect of Pre-operative Exercise Training on Cardiorespiratory Fitness in Patients With Locally Advanced Non-small Cell Lung Cancer Undergoing Induction Chemo-immunotherapy Followed by Surgery - a Randomized Controlled Study

  NCT07479407· Hôpital du Valais· Source

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Incyte Corporation· Source

• Not yet recruiting

  A Study on Remote Health Support for Patients With Heart Failure.

  NCT07440472· Universitat Internacional de Catalunya· Source

• Enrolling by invitation

  Prevalence and Determinants of Obesity in PKU Patients

  NCT07703020· Christel Tran· Source

• Recruiting

  SwissNeuroRehab - HDHI

  NCT07427511· Centre Hospitalier Universitaire Vaudois· Source

• Recruiting

  Early Detection and IntervenTion in Heart Failure

  NCT07731490· University Hospital, Basel, Switzerland· Source

• Not yet recruiting

  Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis

  NCT05105958· Phase 2· University of Zurich· Source

• Recruiting

  A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  NCT07213674· Phase 3· Amgen· Source

• Active, not recruiting

  Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

  NCT07220759· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial

  NCT07263438· Phase 2· Centre Hospitalier Universitaire Vaudois· Source

• Recruiting

  A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  NCT06405087· Phase 3· Takeda· Source

• Active, not recruiting

  Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

  NCT07140900· Phase 1· Amgen· Source

• Active, not recruiting

  Underweight, Overweight, and Linear Growth of Childhood Cancer Patients - the Growth Study

  NCT07750444· Fabiën Belle· Source

• Not yet recruiting

  Deciphering the Mechanisms of Central BP Regulation in Patients With PD Associated With Orthostatic Hypotension

  NCT07139756· Centre Hospitalier Universitaire Vaudois· Source

• Recruiting

  A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  Prospective Evaluation of OptiThyDose

  NCT06864351· University Children's Hospital Basel· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease.

  NCT06831500· Phase 1/2· Julien Bally· Source

• Active, not recruiting

  Lebrikizumab in Moderate-to-severe Atopic Dermatitis

  NCT06906497· Phase 4· Johann E Gudjonsson MD PhD· Source

• Recruiting

  Thyroidectomy for Graves' Disease or Amiodarone-induced Thyrotoxicosis

  NCT06963203· Andrea Goldmann· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Recruiting

  [68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas

  NCT06794372· Phase 2· John O. Prior· Source

• Recruiting

  Closed-Loop Impact on Chronic Kidney Disease in Type 2 Diabetes

  NCT06925217· Heba Al-Alwan· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  68Ga-FAPI-46 in Staging of Pancreatic Adenocarcinoma

  NCT06911021· Centre Hospitalier Universitaire Vaudois· Source

• Recruiting

  A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

  NCT06843447· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  The Dragon PLC Trial (DRAGON-PLC)

  NCT06914648· Maastricht University· Source

• Recruiting

  NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma

  NCT06889766· Phase 1· Centre Hospitalier Universitaire Vaudois· Source

• Recruiting

  Study on Preliminary Safety and Efficacy of Epidural Electrical Stimulation to Manage Lower Urinary Tract Dysfunction After Spinal Cord Injury

  NCT06845904· Ecole Polytechnique Fédérale de Lausanne· Source

• Recruiting

  Reduce Tobacco Use in People Living With HIV in Switzerland

  NCT06789692· University Hospital, Basel, Switzerland· Source

• Recruiting

  Extended vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy. DISSECTION 2.0.

  NCT06776172· University Hospital, Basel, Switzerland· Source

• Active, not recruiting

  EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

  NCT06556563· Phase 3· NovoCure GmbH· Source

• Recruiting

  FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

  NCT06788990· Phase 2/3· Bicara Therapeutics· Source

• Recruiting

  A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

  NCT06100289· Phase 3· Takeda· Source

• Active, not recruiting

  Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

  NCT06691984· Phase 3· Amgen· Source

Showing 50 of 138.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers8 recruiting
• Lung cancer8 recruiting
• Stroke6 recruiting
• High blood pressure5 recruiting
• Parkinson disease5 recruiting
• Prostate cancer5 recruiting
• Atrial fibrillation4 recruiting
• Head and neck cancer4 recruiting
• Melanoma4 recruiting
• Glioblastoma3 recruiting
• Heart failure3 recruiting
• HIV3 recruiting
• Spinal cord injury3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Bladder cancer2 recruiting
• Brain aneurysm2 recruiting
• Bronchiectasis2 recruiting
• Chronic kidney disease2 recruiting
• Congenital heart disease2 recruiting
• Coronary artery disease2 recruiting
• Crohn's disease2 recruiting
• Cytomegalovirus infection2 recruiting
• Graves' disease and hyperthyroidism2 recruiting
• Liver and biliary tract cancer2 recruiting
• Liver cirrhosis2 recruiting
• Multiple system atrophy2 recruiting
• Neuroblastoma2 recruiting
• Obesity2 recruiting
• Ovarian cancer2 recruiting
• Pancreatic cancer2 recruiting
• Sarcoma2 recruiting
• Type 2 diabetes2 recruiting
• Ulcerative colitis2 recruiting
• Acute myeloid leukaemia1 recruiting
• ALS (motor neurone disease)1 recruiting
• Alzheimer disease1 recruiting
• Aortic aneurysm1 recruiting
• Cervical cancer1 recruiting
• Colorectal cancer1 recruiting
• Down syndrome1 recruiting
• Dystonia1 recruiting
• Endometriosis1 recruiting
• Epilepsy1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Hepatitis B1 recruiting
• Hepatitis C1 recruiting
• Hypothyroidism1 recruiting
• Multiple sclerosis1 recruiting
• Polycystic ovary syndrome1 recruiting
• Primary biliary cholangitis1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  Cytokine Adsorption During Complex Cardiac Surgery: a Controlled Randomized Trial

  NCT06512623· Centre Hospitalier Universitaire Vaudois· Source

• Completed

  Development and Feasibility of a Nurse-led Person-centered Education Program

  NCT05715190· School of Health Sciences Geneva· Source

• Terminated

  TYK2 Inhibition in Paradoxical Psoriasis

  NCT06281106· Phase 2/3· Prof Curdin Conrad· Source

• Terminated

  Obstructive Sleep Apnea - Autonomic and Vascular Exploration

  NCT05920083· Raphael Heinzer· Source

• Completed

  A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors

  NCT06403436· Phase 1· TOLREMO therapeutics AG· Source

• Completed

  Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions

  NCT05499832· Phase 3· Insel Gruppe AG, University Hospital Bern· Source

• Completed

  Renal Ultrasound Response After Chocolate Consumption

  NCT05755217· Gregoire Wuerzner; MD· Source

• Completed

  A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05724199· Phase 3· Amgen· Source

• Completed

  Bladder Washing Cytology for Detection of Urothelial Carcinoma Using Catheter or Flexible Cystoscope: Which is Better?

  NCT05643807· Centre Hospitalier Universitaire Vaudois· Source

• Completed

  Theranostics in Soft Tissue Sarcoma Using a Vascular Disruption Approach

  NCT05420727· Phase 1· John O. Prior· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Terminated

  [68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation

  NCT05499637· Phase 2· John O. Prior· Source

• Completed

  Emp-Activity: Empagliflozin Functional Capacity

  NCT05350202· Boehringer Ingelheim· Source

• Terminated

  A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

  NCT05529316· Phase 2· Agenus Inc.· Source

• Completed

  Evaluation of the Use of Thrombopoietin Receptor Agonists in Adults With Primary ITP in Europe

  NCT06408324· European Research Consortium on ITP· Source

• Completed

  Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

  NCT05153239· Phase 3· PharmaMar· Source

• Terminated

  BOBBY™ Balloon Guide Catheter for Endovascular Treatment of Acute Ischemic Stroke

  NCT05361187· Microvention-Terumo, Inc.· Source

• Terminated

  Botulinum Toxin A vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients With Multiple Sclerosis

  NCT04819360· Phase 4· Brigitte Schürch· Source

• Completed

  Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia

  NCT04864795· Vifor (International) Inc.· Source

• Completed

  Dose Escalation Trial of CD40.HIVRI.Env Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Volunteers

  NCT04842682· Phase 1· ANRS, Emerging Infectious Diseases· Source

• Completed

  Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

  NCT04740307· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

  NCT04564547· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.

  NCT04760990· University Hospital, Basel, Switzerland· Source

• Completed

  Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

  NCT04471844· NovoCure Ltd.· Source

• Completed

  A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis

  NCT04497597· AbbVie· Source

• Terminated

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

  NCT04303780· Phase 3· Amgen· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Biogen· Source

• Completed

  Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

  NCT03945773· Phase 2· Ipsen· Source

• Terminated

  FFR-CT to Detect the Absence of Hemodynamically Significant Lesions in Patients With High-risk Acute Coronary Syndrome

  NCT04052763· Centre Hospitalier Universitaire Vaudois· Source

• Completed

  Safety and Efficiency of the YEARS Algorithm Versus Computed Tomography Pulmonary Angiography Alone for Suspected Pulmonary Embolism in Patients With Malignancy

  NCT04657120· Leiden University Medical Center· Source

• Completed

  Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

  NCT03867084· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

  NCT03645928· Phase 2· Iovance Biotherapeutics, Inc.· Source

• Completed

  Computerized Cognitive Training in MS

  NCT03737825· University of California, San Francisco· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Daiichi Sankyo· Source

• Completed

  CERENOVUS Neurothrombectomy Devices Registry

  NCT03685578· Cerenovus, Part of DePuy Synthes Products, Inc.· Source

• Completed

  Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

  NCT03569293· Phase 3· AbbVie· Source

• Completed

  Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma

  NCT03297593· Phase 2· Swiss Cancer Institute· Source

• Completed

  Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M

  NCT03133546· Phase 2· ETOP IBCSG Partners Foundation· Source

• Completed

  STIMO: Epidural Electrical Simulation (EES) With Robot-assisted Rehabilitation in Patients With Spinal Cord Injury.

  NCT02936453· Jocelyne Bloch· Source

• Completed

  Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

  NCT02572843· Phase 2· Swiss Cancer Institute· Source

• Completed

  Cryo Global Registry

  NCT02752737· Medtronic Cardiac Ablation Solutions· Source

• Completed

  Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma

  NCT02205047· Phase 2· European Organisation for Research and Treatment of Cancer - EORTC· Source

• Recruiting

  Physical Activity Program for Reducing Blood Pressure in Sleep Apnea Patients With Resistant Hypertension

  NCT02057783· AGIR à Dom· Source

• Completed

  Derivation and External Validation of the "FORECAST-PC" Prediction Scores

  NCT07750015· Dr. med. Alexander Salerno, MD-PhD· Source

• Completed

  A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer

  NCT02254746· Centre Hospitalier Universitaire Vaudois· Source

• Recruiting

  Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)

  NCT03588286· Western Sydney Local Health District· Source

• Completed

  A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients

  NCT02017717· Phase 3· Bristol-Myers Squibb· Source

• Completed

  ANCHOR (Aneurysm Treatment Using the Heli-FX™ EndoAnchor™ System Global Registry)

  NCT01534819· Medtronic Cardiovascular· Source

• Completed

  ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)

  NCT02078427· Baxalta now part of Shire· Source

Showing 50 of 51.

Conditions

Diseases this institution publishes on or runs trials for.

• Stroke139 works · 15 trials
• Lung cancer94 works · 19 trials
• HIV79 works · 6 trials
• Coronary artery disease40 works · 7 trials
• Multiple sclerosis35 works · 5 trials
• Congenital heart disease23 works · 3 trials
• Depression22 works · 0 trials
• Cytomegalovirus infection17 works · 2 trials
• Insomnia17 works · 0 trials
• Head and neck cancer16 works · 8 trials
• Ventricular tachycardia15 works · 1 trial
• Hypertrophic cardiomyopathy11 works · 0 trials
• Thyroid cancer10 works · 0 trials
• Psoriatic arthritis9 works · 1 trial
• Ankylosing spondylitis8 works · 0 trials
• Peripheral artery disease8 works · 1 trial
• Dystonia7 works · 1 trial
• IgA nephropathy7 works · 0 trials
• Brain aneurysm6 works · 2 trials
• Gout5 works · 0 trials
• Mesothelioma5 works · 0 trials
• Restless legs syndrome4 works · 0 trials
• Multiple system atrophy3 works · 1 trial